J Korean Neurosurg Soc.  2021 May;64(3):469-471. 10.3340/jkns.2020.0188.

Tumor Treating Fields : Additional Mechanisms and Additional Applications

• Kumaria A

• KMID: 2515503
• DOI: http://doi.org/10.3340/jkns.2020.0188

Reference

References

1. Badawy RA, Strigaro G, Cantello R. TMS, cortical excitability and epilepsy: the clinical impact. Epilepsy Res. 108:153–161. 2014.

2. D’Amico RS, Englander ZK, Canoll P, Bruce JN. Extent of resection in glioma-a review of the cutting edge. World Neurosurg. 103:538–549. 2017.

3. Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Ann N Y Acad Sci. 1291:86–95. 2013.

4. Hervey-Jumper SL, Berger MS. Evidence for improving outcome through extent of resection. Neurosurg Clin N Am. 30:85–93. 2019.

5. Hervey-Jumper SL, Berger MS. Maximizing safe resection of low- and high-grade glioma. J Neurooncol. 130:269–282. 2016.

6. Kanner AA, Wong ET, Villano JL, Ram Z; EF-11 Investigators. Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician’s choice chemotherapy. Semin Oncol. 41(Suppl 6):S25–S34. 2014.

7. Kusne Y, Sanai N. The SVZ and its relationship to stem cell based neurooncogenesis. Adv Exp Med Biol. 853:23–32. 2015.

8. Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature. 560:243–247. 2018.

9. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med. 353:811–822. 2005.

10. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.

11. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 318:2306–2316. 2017.

12. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 48:2192–2202. 2012.

13. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 314:2535–2543. 2015.

14. Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, BarnholtzSloan JS, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 23:1985–1996. 2014.

15. Toda H, Hamani C, Fawcett AP, Hutchison WD, Lozano AM. The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. J Neurosurg. 108:132–138. 2008.

16. Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 573:532–538. 2019.

17. Venkatesh H, Monje M. Neuronal activity in ontogeny and oncology. Trends Cancer. 3:89–112. 2017.

18. Venkatesh HS, Johung TB, Caretti V, Noll A, Tang Y, Nagaraja S, et al. Neuronal activity promotes glioma growth through neuroligin-3 secretion. Cell. 161:803–816. 2015.

19. Venkatesh HS, Tam LT, Woo PJ, Lennon J, Nagaraja S, Gillespie SM, et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature. 549:533–537. 2017.

20. Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, et al. Electrical and synaptic integration of glioma into neural circuits. Nature. 573:539–545. 2019.

21. Zeng Q, Michael IP, Zhang P, Saghafinia S, Knott G, Jiao W, et al. Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature. 573:526–531. 2019.

22. Zhang C, Du J, Xu W, Huang H, Gao L. The value of tumor treating fields in glioblastoma. J Korean Neurosurg Soc. 63:681–688. 2020.